RESUMEN
BACKGROUND: Stage IV neuroblastoma is characterized by tumor invasion and metastatic dissemination. Cell lines derived from such neuroblastomas have a high in vitro proliferation capacity. PROCEDURE: We established three neuroblastoma cell lines derived from involved bone marrow of three patients with stage IV neuroblastoma and performed a cytogenetic study. RESULTS: Various culture conditions allowed us to distinguish two cell subpopulations: malignant neuroblasts (Nb-type) and substrate-adherent stromal cells (Str-type). Karyotypic analyses revealed two specific chromosomal abnormalities in diploid malignant IGR-N-331 neuroblasts, der(1)t(1;7)(p22;q11) and der(5)t(5;17)(q35;q21), one unbalanced translocation der(1)t(1;17)(p35;q21)x2 in hyperdiploid malignant IGR-N-337 neuroblasts, and a normal karyotype in both corresponding stromal subpopulations. In contrast, in the IGR-N-91 model, both cell types shared two unbalanced translocations, t(1;4)(q12;p15) and t(2;10)(p14;q11), suggesting that stromal cells and malignant neuroblasts originate from a common stem cell. CONCLUSIONS: Based on our findings, we postulate that genetically modified stromal cells may influence the metastatic potential of malignant neuroblasts.
Asunto(s)
Células de la Médula Ósea/ultraestructura , Aberraciones Cromosómicas , Cromosomas Humanos/ultraestructura , Neuroblastoma/patología , Células Cultivadas/ultraestructura , Cromosomas Humanos/genética , Cromosomas Humanos Par 1/genética , Cromosomas Humanos Par 1/ultraestructura , ADN de Neoplasias/genética , Progresión de la Enfermedad , Amplificación de Genes , Genes myc , Humanos , Hibridación Fluorescente in Situ , Lactante , Cariotipificación , Pérdida de Heterocigocidad , Células Madre Neoplásicas/ultraestructura , Neuroblastoma/genética , Células del Estroma/ultraestructura , Células Tumorales CultivadasRESUMEN
A series of 23 children with primitive neuroectodermal tumours (PNET) were analysed with comparative genomic hybridization (CGH). Multiple chromosomal imbalances have been detected in 20 patients. The most frequently involved chromosome was chromosome 17, with a gain of 17q (11 cases) and loss of 17p (eight cases). Further recurrent copy number changes were detected. Extra copies of chromosome 7 were present in nine patients and gains of 1q were detected in six patients. A moderate genomic amplification was detected in one patient, involving two sites on 3p and the whole 12p. Losses were more frequent, and especially involved the chromosomes 11 (nine cases), 10q (eight cases), 8 (six cases), X (six patients) and 3 (five cases), and part of chromosome 9 (five cases). These recurrent chromosomal changes may highlight locations of novel genes with an important role in the development and/or progression of PNET.
Asunto(s)
Aberraciones Cromosómicas/genética , Genoma Humano , Tumores Neuroectodérmicos Primitivos/genética , Neoplasias Supratentoriales/genética , Adolescente , Niño , Preescolar , Trastornos de los Cromosomas , Femenino , Humanos , Lactante , Masculino , Meduloblastoma/genética , Hibridación de Ácido Nucleico , RecurrenciaRESUMEN
Metastatic stage IV neuroblastoma tumors, as well as cell lines derived from them, are highly malignant and rapidly fatal. To determine whether malignant potential of these cells might be influenced by stromal tissue at sites frequently involved in metastasis, we initiated primary cultures from bone marrow of three patients (331, 337, and 91) with stage IV neuroblastoma. All three explants contained two distinct cell populations, malignant neuroblasts (Nb-type) and substrate adherent stromal-like (Str-type) cells. The cell types were separated at the first passage and studied by cytogenetic, molecular, and immunocytochemical methods. Karyotypic analyses after 3-6 passages in vitro revealed the presence of unique chromosomal abnormalities in Nb-type cells of all three lines: (1) der(1)t(1;7) (p32;q11) and der(5)t(5;17)(q35;q21) in pseudodiploid IGR-N-331 neuroblasts; (2) der(1)t(1;17)(p35;q21-22) x 2 and der(7)t(7;7)(p21;q21) in IGR-N-337 hyperdiploid neuroblasts; and (3) more than six rearranged chromosomes in two related subpopulations of hypodiploid IGR-N-91 neuroblasts. Neuroblastic cells from all three tumors amplified MYCN 25- to 50-fold (with amplified genes visible as dmin or, in one IGR-N-91 subline, as an hsr(14)[q32]) and expressed N-CAM. Str-type cells from tumors 331 and 337 had a normal diploid karyotype, did not express either N-CAM or S-100, and are probably normal bone marrow fibroblasts. By contrast, S-100 negative Str-type IGR-N-91 cells were hypodiploid and shared at least two unbalanced translocations, der(4)t(1;4)(q12;p15) and der(2)t(2;10;17)(p14;q11;q22), with neuroblastic counterparts, indicating that "stromal" cells and malignant neuroblasts had a common tumor cell origin. Thus, the Str-type cells of IGR-N-91 are examples of S-type phenotypic variants frequently described for long-term human neuroblastoma cells lines in vitro, but not previously observed in vivo.
Asunto(s)
Neoplasias Óseas/genética , Neuroblastoma/genética , Neoplasias Óseas/patología , Neoplasias Óseas/secundario , Genotipo , Humanos , Inmunohistoquímica , Cariotipificación , Fenotipo , Células Tumorales CultivadasRESUMEN
Fotemustine is a chloroethylnitrosourea with antitumor activity in disseminated melanoma and adult primary brain tumors. Because new drugs are required for the treatment of medulloblastoma in children, we evaluated the preclinical antitumor activity of fotemustine in four s.c. medulloblastoma xenografts, in comparison with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Both drugs were administered as a single i.p. injection to nude mice bearing advanced-stage tumor. Fotemustine displayed significant antitumor activity in three of four medulloblastoma xenografts; two, IGRM34 and IGRM57, were highly sensitive, with 37 and 100% tumor-free survivors, respectively, more than 120 days after treatment at the highest nontoxic dose (50 mg/kg). Fotemustine was also highly active in a malignant glioma xenograft (IGRG88; five of six tumor-free survivors on day 177). Fotemustine proved to be significantly more active than BCNU in IGRM34 and the glioma xenograft IGRG88. The DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase) was detected in all tumor xenografts, ranging in activity from 6 to 892 fmol/mg protein. The high in vivo sensitivity to fotemustine and BCNU observed in three xenografts was clearly associated with a low ATase activity (> 20 fmol/mg), whereas the two poorly sensitive or refractory medulloblastoma xenografts showed high ATase activity (> 500 fmol/mg). Alkylpurine-DNA N-glycosylase activity was detected in all tumor xenografts but at levels ranging only from 513 to 1105 fmol/mg/h; no consistent relationship was found between alkylpurine-DNA N-glycosylase activity and the in vivo sensitivity to the two chloroethylnitrosoureas. The improved activity and tolerance of fotemustine in comparison with BCNU in pediatric medulloblastoma xenografts strongly support the clinical development of this agent in children with brain tumors, in which ATase should be examined as a potential prognostic indicator.
Asunto(s)
Antineoplásicos/farmacología , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/enzimología , Neoplasias Cerebelosas/tratamiento farmacológico , Neoplasias Cerebelosas/enzimología , ADN Glicosilasas , Glioma/tratamiento farmacológico , Glioma/enzimología , Meduloblastoma/tratamiento farmacológico , Meduloblastoma/enzimología , N-Glicosil Hidrolasas/metabolismo , Compuestos de Nitrosourea/farmacología , O(6)-Metilguanina-ADN Metiltransferasa/metabolismo , Compuestos Organofosforados/farmacología , Animales , Antineoplásicos/toxicidad , Antineoplásicos Alquilantes/farmacología , Carmustina/farmacología , Reparación del ADN , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Humanos , Masculino , Ratones , Persona de Mediana Edad , Trasplante de Neoplasias , Compuestos de Nitrosourea/toxicidad , Compuestos Organofosforados/toxicidad , Trasplante Heterólogo , Células Tumorales CultivadasRESUMEN
PURPOSE: The aim of this phase II trial was to assess the efficacy of fludarabine monophosphate in untreated and pretreated mantle-cell lymphomas (MCL). PATIENTS AND METHODS: Fifteen patients with MCL were included in the study. In two cases, fludarabine was the first-line therapy, the second in four cases, the third in five cases, and the fourth in four cases. The diagnosis of MCL was based on the criteria of the European Lymphoma Task Force (ELTF), with morphologic, immunologic, and cytogenetic data. Patients were treated with intravenous fludarabine 25 mg/m2/d for 5 days every 4 weeks. RESULTS: Toxicity of fludarabine was mild: World Health Organization (WHO) grade 3 and 4 granulocytopenia occurred in 15 of 56 assessable cycles (cy) (27%), there was no grade 3 or 4 thrombocytopenia, one grade 3 bacterial lung infection, and no treatment-related death. There were five partial responses (33%) but no complete response. The duration of these responses was short and ranged from 4 to 8 months. CONCLUSION: These results suggest that fludarabine can be moderately effective in the treatment of MCL. Fludarabine appears to be far less effective than in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL). Therefore, fludarabine should be evaluated in association with other chemotherapeutic agents in MCL.
Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Linfoma no Hodgkin/tratamiento farmacológico , Fosfato de Vidarabina/análogos & derivados , Adulto , Anciano , Antimetabolitos Antineoplásicos/efectos adversos , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fosfato de Vidarabina/efectos adversos , Fosfato de Vidarabina/uso terapéuticoRESUMEN
We reviewed 77 cases considered as lymphocytic lymphomas of intermediate differentiation or diffuse centrocytic lymphomas. Forty-five cases were diagnosed as mantle cell lymphoma (MCL). The architectural pattern was diffuse in 95%, 8 cases presented large blastoid cells and CD5 positivity was observed in 28/34 cases. Of 20 cases studied, 8 presented a t(11;14)(q13;q32). Patient characteristics were: median age 59 years, B symptoms in 38%, 87% stages III-IV, bone marrow involvement in 67% with peripheral leukemic cells in 24%. Forty-four patients were treated with chemotherapy and 7 received radiotherapy. The complete response (CR) rate was 58%. Of the 26 CR, 19 relapsed at a median of 15 months. Disease-free survival was 42% and overall survival was 73% at 3 years. In a univariate analysis, overall survival was related to liver and bone marrow involvement, the presence of peripheral lymphomatous cells and achieving a complete response.
Asunto(s)
Leucemia Linfocítica Crónica de Células B/patología , Linfoma no Hodgkin/patología , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Linfocítica Crónica de Células B/terapia , Linfoma no Hodgkin/genética , Linfoma no Hodgkin/terapia , Masculino , Persona de Mediana Edad , PronósticoRESUMEN
Secondary therapy-related, acute lymphoblastic leukemia (S-ALL) is less common than its myeloblastic counterpart. S-ALL with MLL gene rearrangements have only been reported on six previous occasions. Only three of these had t(4;11)(q21;23) S-ALL with MLL-AF4 fusion transcript has only been reported in one earlier case. In this report a rare case of S-ALL with MLL-AF4 transcript is described in a 36 year old woman treated for breast carcinoma with chemotherapy which included the topoisomerase II inhibitor, VP-16. The precise incidence of MLL gene rearrangement in S-ALL still remains to be clarified.
Asunto(s)
Proteínas de Unión al ADN/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Proto-Oncogenes , Inhibidores de Topoisomerasa II , Factores de Transcripción , Translocación Genética , Adulto , Antineoplásicos Fitogénicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Cromosomas Humanos Par 11 , Resistencia a Antineoplásicos , Etopósido/uso terapéutico , Femenino , Reordenamiento Génico , N-Metiltransferasa de Histona-Lisina , Humanos , Proteína de la Leucemia Mieloide-Linfoide , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Recurrencia , Inducción de RemisiónRESUMEN
DNA-topoisomerase I is the nuclear target of new anticancer drugs, namely camptothecin and its derivatives. In order to establish the rational basis for their clinical development in paediatric oncology, the antitumour activity of irinotecan (CPT-11) and topotecan, two camptothecin water-soluble derivatives, was studied in nude mice bearing neuroblastoma xenografts. The panel was composed of 4 previously established subcutaneous xenograft lines (IGR-N835, IGR-N91, IGR-NB3, IGR-NB8) that exhibited the common biological markers of poor prognosis in children (MYCN amplification, 1p deletion, paradiploidy and/or MDR1 overexpression). Irinotecan and topotecan were administered i.v. or i.p. over 5 consecutive days in animals bearing tumours. Irinotecan (40 mg/kg/day) induced 20-100% complete regressions with tumour growth delays ranging from 20 to 46 days. Two out of 10 IGR-N91 bearing animals were tumour free more than 120 days after treatment with the top dose (50 mg/kg/day). Topotecan (2.7 mg/kg/day) induced 0-67% complete regressions with tumour growth delays ranging from 23 to 50 days. One out of 8 IGR-NB3 bearing mice was tumour free at the end of the experiment. The antitumour activity of both drugs was clearly sustained at a lower dose level. Topoisomerase I activity was assayed in 15 neuroblastomas, 3 ganglioneuroblastomas and 2 normal adrenal glands, using a DNA relaxation assay. Topoisomerase I activity ranged from 69 to 1304 arbitrary units/mg of protein, and was significantly higher in immature neuroblastomas than in ganglioneuroblastomas and adrenal glands. In conclusion, irinotecan and topotecan are active against neuroblastoma xenografts. Their target is expressed in patients' tumour samples. Clinical development of topoisomerase I inhibitors in children with neuroblastoma is warranted.
Asunto(s)
Antineoplásicos/uso terapéutico , Camptotecina/análogos & derivados , ADN-Topoisomerasas de Tipo I/efectos de los fármacos , Proteínas de Neoplasias/efectos de los fármacos , Neuroblastoma/tratamiento farmacológico , Topotecan/uso terapéutico , Glándulas Suprarrenales/enzimología , Animales , Camptotecina/uso terapéutico , Niño , Preescolar , ADN-Topoisomerasas de Tipo I/metabolismo , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Ganglioneuroblastoma/enzimología , Humanos , Irinotecán , Masculino , Ratones , Ratones Desnudos , Proteínas de Neoplasias/metabolismo , Neuroblastoma/enzimología , Inducción de Remisión , Trasplante HeterólogoRESUMEN
Neuroblastoma shows remarkable heterogeneity, ranging from spontaneous regression to progression toward highly malignant tumors. In search of genetic abnormalities that could explain this variability, we have characterized neuroblastoma tumors by using multiple fluorescent hybridizations. Our results indicate that chromosome 17 is rearranged very frequently in the form of unbalanced translocations with numerous chromosomal partners, all leading to the presence of supernumerary copies of a 25 Mb chromosomal region originating from 17q23.1-qter. Additional 17q material was detected in more than 90% of untreated high-grade neuroblastomas and, along with 1p36 deletion, should represent the most frequent genetic abnormality of neuroblastoma observed until now.
Asunto(s)
Cromosomas Humanos Par 17 , Neuroblastoma/genética , Southern Blotting , Neoplasias de la Médula Ósea/genética , Aberraciones Cromosómicas , Trastornos de los Cromosomas , Cromosomas Artificiales de Levadura , Cromosomas Humanos Par 14 , Humanos , Hibridación Fluorescente in Situ , Linfoma/genética , PronósticoRESUMEN
The anti-tumour activity of CPT-11, a topoisomerase I inhibitor, was evaluated in four human neural-crest-derived paediatric tumour xenografts; one peripheral primitive neuroectodermal tumour (pPNET) (SK-N-MC) and three neuroblastomas. Two models, SK-N-MC and IGR-N835, were established in athymic mice from a previously established in vitro cell line. Two new neuroblastoma xenograft models, IGR-NB3 and IGR-NB8, were derived from previously untreated non-metastatic neuroblastomas. They exhibited the classic histological features of immature neuroblastoma along with N-myc amplification, paradiploidy, chromosome 1p deletions and overexpression of the human mdr 1 gene. These tumour markers have been shown to be poor prognostic factors in children treated for neuroblastoma. CPT-11 was tested against advanced stage subcutaneous tumours. CPT-11 was administered i.v. using an intermittent (q4d x 3) and a daily x 5 schedule. The optimal dosage and schedule was 40 mg kg-1 daily for 5 days. At this highest non-toxic dose, CPT-11 induced 100% tumour-free survivors on day 121 in mice bearing the pPNET SK-N-MC xenograft. For the three neuroblastoma xenografts, 38-100% complete tumour regressions were observed with a tumour growth delay from 38 to 42 days, and anti-tumour activity was clearly sustained at a lower dosage (27 mg kg-1 day-1). The efficacy of five anti-cancer drugs commonly used in paediatric oncology or in clinical development was evaluated against SK-N-MC and IGR-N835. The sensitivity of these two xenografts to cyclophosphamide, thiotepa and cisplatin was of the same order of magnitude as that of CPT-11, but they were refractory to etoposide and taxol. In conclusion, CPT-11 demonstrated significant activity against pPNET and neuroblastoma xenografts. Further clinical development of CPT-11 in paediatric oncology is warranted.
Asunto(s)
Antineoplásicos Fitogénicos/uso terapéutico , Camptotecina/análogos & derivados , Neuroblastoma/tratamiento farmacológico , Tumores Neuroectodérmicos Periféricos Primitivos/tratamiento farmacológico , Tumores Neuroectodérmicos Primitivos/tratamiento farmacológico , Animales , Antineoplásicos/uso terapéutico , Camptotecina/uso terapéutico , Línea Celular , Cisplatino/uso terapéutico , Ciclofosfamida/uso terapéutico , Supervivencia sin Enfermedad , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos , Etopósido/uso terapéutico , Femenino , Humanos , Irinotecán , Ratones , Ratones Desnudos , Neuroblastoma/patología , Tumores Neuroectodérmicos Primitivos/patología , Tumores Neuroectodérmicos Periféricos Primitivos/patología , Paclitaxel/uso terapéutico , Tiotepa/uso terapéutico , Inhibidores de Topoisomerasa I , Trasplante HeterólogoRESUMEN
Genistein, an isoflavonoid derivative initially described as an in vitro protein tyrosine kinase inhibitor, also inhibits mammalian DNA topoisomerase II both in vitro and in vivo. From a human leukaemic T cell line (CCRF-CEM), two genistein-resistant cell lines, which grow in the presence of 50 and 150 microM genistein, respectively, were selected and designated CEM/GN50 and CEM/GN150. Flow cytometry and karyotype analyses revealed that more than 95% of the parental cells were tetraploid whereas both resistant sublines were essentially diploid and were likely derived from the diploid fraction in the initial population. The CEM/GN cells were 3- to 4-fold resistant to genistein, and highly cross-resistant to certain metabolic inhibitors such as cytosine-arabinoside (50-fold) and 5-fluoro-2'-deoxyuridine (5000-fold). This resistance was associated with a markedly decreased uptake of thymidine and a 10-fold reduction in thymidine kinase activity. The CEM/GM cells were also 15- to 30-fold cross-resistant to topoisomerase inhibitors (etoposide, m-AMSA, 2-Me-9-OH-ellipticinium). Comparison of topoisomerase II activities in the sensitive and resistant cells showed: (i) an approximately 2-fold reduced decatenation activity in nuclear extracts from the resistant cells; (ii) an approximate 30% reduction in DNA-protein cross-links in etoposide-treated resistant cells; and (iii) a markedly reduced expression of the topoisomerase II beta isoform. These data, consistent with our previous results, indicate that the cytotoxicity of genistein is at least in part related to its capacity to inhibit DNA topoisomerase II.
Asunto(s)
Isoenzimas/antagonistas & inhibidores , Isoflavonas/farmacología , Inhibidores de Topoisomerasa II , Animales , ADN-Topoisomerasas de Tipo II/genética , Diploidia , Resistencia a Medicamentos , Femenino , Citometría de Flujo , Floxuridina/metabolismo , Floxuridina/farmacología , Genisteína , Humanos , Cariotipificación , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/enzimología , Células Tumorales Cultivadas/ultraestructuraRESUMEN
Cytogenetic analysis of a case of synchronous bilateral seminoma revealed, for each tumor, a chromosomal hypotetraploid mode with gain and loss of chromosomes and only one structural rearrangement, del(1p) and i(12p), which were secondary chromosomal events for the left and right tumors, respectively. This study allowed us to discriminate between a sole or independent origin for these two tumors.
Asunto(s)
Neoplasias Primarias Múltiples , Seminoma/genética , Neoplasias Testiculares/genética , Adulto , Humanos , Hibridación Fluorescente in Situ , Cariotipificación , MasculinoRESUMEN
BACKGROUND: Some genetic alterations have been shown to have prognostic implication for patients with neuroblastoma: MYCN oncogene amplification, deletion of the short arm of chromosome 1 and di- or tetraploidy. The goal of this study was to analyze these factors in children with neuroblastoma. METHODS: Twenty neuroblastoma samples were analyzed with morphologic cytogenetics, and each of them was compared with MYCN amplification status by Southern blot and fluorescent in situ hybridization (FISH) with a genomic probe. RESULTS: A complete karyotype was obtained for 14 children. A diploid or tetraploid mode and a 1p deletion were found in most children with advanced stages. MYCN amplification status was totally concordant with both methods in all patients, even in a case with low level amplification. A wide intercellular variation in the amplification level in each MYCN amplified sample was shown. CONCLUSION: The use of FISH to assess MYCN amplification rapidly in neuroblastoma is recommended. This method could be very useful in future therapeutic protocols in which treatment is based on MYCN status (and especially for infants and children with localized tumor).
Asunto(s)
Aberraciones Cromosómicas , Neuroblastoma/genética , Adolescente , Niño , Preescolar , Amplificación de Genes , Genes myc , Humanos , Hibridación Fluorescente in Situ , Lactante , Neuroblastoma/patologíaAsunto(s)
Trasplante de Médula Ósea , Quimera/genética , Hibridación Fluorescente in Situ , Macrófagos Alveolares/ultraestructura , Adolescente , Adulto , Trasplante de Médula Ósea/patología , Humanos , Leucemia Mieloide Aguda/terapia , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Sexo , Trasplante Homólogo , Cromosoma X , Cromosoma YRESUMEN
Short-term cultures from 38 follicular thyroid adenomas revealed clonal numerical and/or structural chromosomal changes in 8 tumors, nonclonal changes in 1 tumor, and only normal karyotypes in 29 tumors. Three cases had trisomy 22 as the sole anomaly. Two cases had a combination of trisomies for chromosomes 5, 7, 9, 12, and 16.
Asunto(s)
Adenoma/genética , Aberraciones Cromosómicas , Trastornos de los Cromosomas , Cromosomas Humanos Par 22 , Neoplasias de la Tiroides/genética , Trisomía , Adenoma/patología , Adulto , Bandeo Cromosómico , Mapeo Cromosómico , Femenino , Humanos , Cariotipificación , Masculino , Persona de Mediana Edad , Neoplasias de la Tiroides/patologíaRESUMEN
A new permanent cell line (GLAG-66) has been established from the metastases of a papillary thyroid carcinoma in a male patient. Herein are reported the cytogenetic characteristics of this new cell line, which is tumorigenic in athymic mice. An aneuploid chromosomal pattern was observed (48 chromosomes) with various chromosomal abnormalities. The karyotype was: 48,XY,der(1)t(9;1;9), +der(8)t(1;8),der(9)t(1;9),der(9)t(1;9), +14. This cell line should prove to be of great value in the study of the biology of human papillary thyroid carcinomas.
Asunto(s)
Aneuploidia , Carcinoma Papilar/genética , Aberraciones Cromosómicas , Neoplasias de la Tiroides/genética , Animales , Línea Celular , Humanos , Cariotipificación , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Trasplante de Neoplasias , Trasplante HeterólogoRESUMEN
Short-term cultures from 19 papillary thyroid adenocarcinomas revealed clonal numerical and/or structural chromosomal changes in 13 tumors, nonclonal abnormalities in one tumor, and only normal karyotypes in five tumors. Clonal abnormalities of chromosome 10 were present in three tumors, two of which had the translocation t(7;10)(q35;q21). Numerical abnormalities of chromosome 17 were detected in two tumors.
Asunto(s)
Adenocarcinoma Papilar/genética , Aberraciones Cromosómicas , Cromosomas Humanos Par 10 , Neoplasias de la Tiroides/genética , Adulto , Cromosomas Humanos Par 17 , Cromosomas Humanos Par 7 , Femenino , Humanos , Cariotipificación , Masculino , Persona de Mediana EdadRESUMEN
Two T-cell acute lymphoblastic leukemia (ALL) cell lines, PEER and CCRF-CEM, were studied by various chromosome banding techniques, including 5-bromodeoxyuridine (BrdU) incorporation methods. Although of very similar origin, these two cell lines behave quite differently. In particular, CEM cell line exhibited an abnormal replication banding pattern (RBP) and poor sister chromatid differentiation (SCD). Study of their thymidylate synthase and thymidine kinase activities indicated that CEM had a more active salvage pathway for thymidylate synthesis than did PEER cell line, which may suggest an efficient BrdU incorporation and its fast decrease in culture medium, resulting in the observed peculiarities. However, this was contradictory to the fact that CEM need a higher dose of BrdU than do PEER cells to induce SCD and RBP. Finally, the radioactivity from 3H-thymidine decreased in the culture medium much faster for PEER cell line than for CEM cell line, and about 50% of the remaining radioactivity was due to 3H-thymidine for CEM cell line. Thus, the abnormal SCD and RBP are explained by an active catabolism of thymidine and BrdU in CEM cell line.
Asunto(s)
Bromodesoxiuridina/metabolismo , Bandeo Cromosómico , Leucemia-Linfoma de Células T del Adulto/genética , Intercambio de Cromátides Hermanas , Humanos , Cariotipificación , Leucemia-Linfoma de Células T del Adulto/metabolismo , Hibridación de Ácido Nucleico , Timidina Quinasa/metabolismo , Timidilato Sintasa/metabolismo , Células Tumorales CultivadasRESUMEN
Cytogenetic investigations using short-term cultures are reported in six thyroid adenomas. Clonal and nonclonal numerical chromosomal changes were present in two tumors. In two of the four remaining, nonclonal numerical and structural abnormalities were observed, whereas only normal karyotypes were found in the other two. Chromosome 10 and 17 were involved in several cases, although no common clonal changes could be detected. The present studies show that thyroid adenomas, benign tumors of an endocrine gland, may have chromosomal abnormalities, as described for other benign tumors.
Asunto(s)
Adenoma/genética , Aberraciones Cromosómicas , Trastornos de los Cromosomas , Neoplasias de la Tiroides/genética , Adenoma/patología , Adulto , Femenino , Humanos , Cariotipificación , Masculino , Persona de Mediana Edad , Neoplasias de la Tiroides/patología , Células Tumorales CultivadasRESUMEN
A high resolution chromosome banding method was applied to define the karyotype of the PEER cell line. It was found significantly different from that previously described, and can be characterized as follows: 46,XX,-4, del(5) (q21q23), del(6)(q14q22), del(9)(p12p21), i(9p), +der(4) rea(4) involving a large duplication of 4q. The cell cycle duration varies in relation to the time after splitting, slow from 0 to 48 h and faster from 48 to 96 h. The average time found was 25 h with durations of 6 and 15 h for G2 and S-phases, respectively. This variable cell cycle led us to change the conditions of BrdU incorporation to obtain a convenient R-banding. According to our own experience, this can be transposed to many other malignant cells to obtain a high resolution chromosome banding.